obesity drug news today october 2025 glp-1 GLP-1 Agonists Weight Loss Drugs Market Size Report, 2030 Obesity GLP-1 Market
Description
The TRIUMPH program includes studies examining weight loss outcomes, cardiovascular endpoints, and comorbidity improvements like osteoarthritis pain relief
Emerging technologies such as proteomics and integrated multi-omics analyses are beginning to transform diagnostic approaches [55]
All GLP-1 RA labels mention to monitor for pancreatitis signs
Within this framework, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), originally developed for the treatment of type 2 diabetes (T2D), have recently shown cardioprotective effects beyond their role in glycaemic control
A total of 26 articles were identified as of October 8, 2024
